Nephrocare Health Services Ltd (NEPHROPLUS) is currently trading at 603.55 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Nephrocare Health Services Limited operates an integrated dialysis-care platform spanning in-clinic haemodialysis, home dialysis, mobile services, hospital-linked clinics, government PPPs, pharmacy support, and patient wellness programs across six countries. The company delivered H1FY27 revenue growth of 23.6% to ₹585.2 crore, with treatments rising 12.6% and revenue per treatment increasing 9.7%. This combination indicates that growth is being driven by both network utilization and pricing or service-mix improvement. International operations now contribute 47% of quarterly revenue, a striking increase from 12% in FY23. The Philippines, Uzbekistan, Saudi Arabia, Nepal, and the newly entered Kazakhstan provide geographic diversification, although newer markets are likely to experience temporary margin dilution. Nephrocare Health Services Limited combines scale with an asset-light model: approximately 51% of its clinics operate under revenue-sharing or partnership structures, while around 80% of Indian clinics are located in tier-II and tier-III cities and towns. The company is expanding beyond conventional centre-based care through home haemodialysis, peritoneal dialysis pilots, cloud-enabled Renova technology, automated patient feedback, and data-led clinical tools, while simultaneously investing in clinical training and international talent development.

Over the past 52 weeks, Nephrocare Health Services Ltd has traded between a low of ₹445.00 and a high of ₹781.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Nephrocare Health Services Ltd has a market capitalization of approximately 6,069.24. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Nephrocare Health Services Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 47.38 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 6,069.24 Cr, Nephrocare Health Services Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Nephrocare Health Services Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Nephrocare Health Services Ltd is 47.38. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

NephroPlus said its acquisition of two Almaty clinics gives it a base to understand Kazakhstan's local market conditions. The clinics have 34 machines, and management said it will assess the wider Central Asian opportunity before scaling the network.

NephroPlus reported consolidated revenue of Rs 585.2 crore in H1FY27. This was 23.6% higher than Rs 473.5 crore in H1FY26. The company linked the increase to treatment-volume growth and higher revenue per treatment.

NephroPlus entered Kazakhstan with two acquired standalone clinics in Almaty. The two sites have 34 machines and perform more than 1,200 monthly sessions, according to the presentation. Management has not disclosed a target number of Kazakhstan clinics.

NephroPlus reported revenue from operations of Rs 585.2 crore in H1FY27. This was 23.6% higher than Rs 473.5 crore in H1FY26. The increase coincided with growth in treatments and RPT.